SYNthesis BioVentures

SYNthesis BioVentures is a registered ESVCLP fund focused on early-stage therapeutics, investing in projects from discovery through preclinical proof of concept and IND enabling studies. We invest in small molecule therapeutics, biologics, and cell and gene therapies for indications with significant unmet needs. Continuity of Capital By investing in projects from inception through to pre-IPO, we intend to facilitate the continuity of capital from Australian academia to venture financing and through Australian capital markets. 1. Deal Flow - Capitalise on SYNthesis’ inside look into partner project pipelines to source cutting edge. - Best/First-in-class therapeutics targeting areas of high-value clinical unmet need. 2. Invest in early-stage therapeutics - Discovery through early clinical development. - Investing in seed, A, and pre-IPO financings. 3. Actively manage our portfolio companies - Integrate investees into SYNthesis’ existing management and R&D operations. - Realise economies of scale by leveraging the SYNthesis Group’s existing resources. 4. Pursue exits across the development spectrum - We have expertise in generating successful exits in early-stage assets. - Aim for liquidity through partnerships, M&A, and public listings.